NeOnc's NEO100 Shows Enhanced Brain Tumor Efficacy When Combined with Ultrasound in AI-Driven Study
核心洞察
NeOnc Technologies announced preclinical findings showing that ultrasound significantly enhances NEO100's therapeutic potency against multiple primary and metastatic brain tumor types.
An AI-driven neural network trained on over 200 molecular descriptors consistently identified NEO100 as a leading sonosensitizer for focused ultrasound therapy.
Validation studies using 3D-bioprinted tumor organoids demonstrated markedly enhanced tumor-killing activity when NEO100 was combined with focused ultrasound parameters.
NeOnc Technologies Holdings, Inc. (搜索) (Nasdaq: NTHI) has announced breakthrough preclinical findings demonstrating that ultrasound significantly amplifies the therapeutic potency of NEO100, its brain-penetrant therapeutic for central nervous system cancers (搜索). The study, published on bioRxiv and conducted through a research collaboration at the University of Southern California (USC), shows strong antitumor effects across multiple primary and metastatic brain tumor types when NEO100 is combined with focused ultrasound.
AI-Driven Discovery Platform Identifies NEO100 as Leading Sonosensitizer
The research utilized an innovative AI-driven, 3D-bioprinted New Approach Methodology (NAM) led by Dr. Josh Neman, Associate Professor of Neurological Surgery at USC and Chief Clinical Officer of NTHI. The NAM platform is built on NTHI's patented rapid magnetic 3D bioprinting technology (US Patent 11,788,057), which enables the rapid generation of physiologically relevant patient-derived tumor organoids within hours rather than the weeks typically required by conventional methods.
An AI-driven positive-unlabeled neural network, trained on over 200 molecular descriptors, was employed to predict compounds most likely to respond to focused ultrasound, penetrate the blood-brain barrier (搜索), and exhibit potent sonodynamic therapeutic activity. Throughout this extensive AI screening initiative, the platform consistently identified NEO100 as a leading predicted sonosensitizer.
Validation Studies Demonstrate Enhanced Tumor-Killing Activity
Validation studies conducted on rapidly bioprinted tumor spheroids showed promising results across multiple brain tumor types. The research included testing on glioblastoma (搜索), pediatric medulloblastoma (搜索), high-grade meningioma (搜索), and breast- and lung-to-brain metastases (搜索). NEO100 displayed markedly enhanced tumor-killing activity when combined with focused ultrasound parameters across all tested tumor types.
"This breakthrough provides strong external validation for NEO100's potential as a first-in-class, noninvasive sonodynamic therapeutic. The integration of AI, 3D bioprinting, and ultrasound significantly expands NEO100's commercial and clinical opportunity beyond current indications," said Amir Heshmatpour, Executive Chairman and President of NTHI.
Clinical Development Pipeline
NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing central nervous system therapeutics designed to overcome blood-brain barrier (搜索) challenges. The company's NEO drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038.
Currently, NeOnc's NEO100 and NEO212 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various cancer types and in clinical trials treating malignant gliomas (搜索).
Future Clinical Applications
The research findings support moving NEO100 combined with focused ultrasound into future clinical trials for a wide range of primary and metastatic brain tumors. This approach represents a potential advancement in sonodynamic therapy, offering a noninvasive treatment option for brain cancer patients.
The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.